

IMPORTANT NOTICE

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR OTHERWISE THAN TO PERSONS TO WHOM IT CAN LAWFULLY BE DISTRIBUTED. THIS OFFERING IS AVAILABLE ONLY TO ADDRESSEES OUTSIDE OF THE UNITED STATES, SUBJECT TO CERTAIN RESTRICTIONS.

IMPORTANT: You must read the following before continuing. The following applies to the document following this page (the "**Document**"; the Document together with the offering circular dated 1 April 2011 relating to an offering of mondoBIOTECH holding AG (the "**Offering Circular**") and any other documents relating to such offering, the "**Offer Documents**"), and you are therefore advised to read this carefully before reading, accessing or making any other use of the Document. In accessing the Document, you agree to be bound by the following terms and conditions, including any modifications to them anytime you receive any information from us as a result of such access.

NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "**SECURITIES ACT**"), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE U.S. AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT ("**REGULATION S**").

NEITHER THIS DOCUMENT NOR ANY OTHER OFFER DOCUMENT MAY BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON NOR REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT OR ANY OTHER OFFER DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.

For a description of certain restrictions in other jurisdictions regarding the offering and sale of the securities described in the Offering Circular, see the section entitled "Selling and Transfer Restrictions" of the Offering Circular.

Confirmation of your Representation: In order to be eligible to view this Document or make an investment decision with respect to the securities described in the Offer Documents, investors must be engaging in an offshore transaction in accordance with Rule 903 or 904 of Regulation S. You have been sent the attached Document on the basis that you have confirmed to mondoBIOTECH holding AG, (i) that you and any customers that you represent are engaging in an offshore transaction in accordance with Rule 903 or 904 of Regulation S and (ii) that you consent to delivery by electronic transmission.

You are reminded that the attached Document has been delivered to you on the basis that you are a person into whose possession the Document may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not, nor are you authorised to, deliver the Document to any other person. The materials relating to the offering do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law.

The attached Document has been made available to you in electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently neither mondoBIOTECH holding AG nor any director, officer, employee nor agent of them or affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the Document distributed to you in electronic format and the hard copy version available to you on request from mondoBIOTECH holding AG who made available to you the Document in electronic form.

The materials relating to the offering do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. Also, there are restrictions on the distribution of the attached Document and the Offer Documents and/or the offer or sale of securities in the member states of the European Economic Area. The Document and the Offer Documents may only be communicated to persons in the United Kingdom who (i) have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (as amended, the "**Financial Promotion Order**"), (ii) are persons falling within Article 49(2)(a) to (d) ("**high net worth companies, unincorporated associations, etc.**") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA in connection with the issue or sale of any Subscription Rights or Offer Shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "**relevant persons**").



OFFERING CIRCULAR
mondobiotech holding AG
(a stock corporation under Swiss law)

Offer Size Supplement

Offering of up to 354'038 registered common shares with a nominal value of CHF 0.10 each

This supplement (the "**Supplement**") is a supplement to the Offering Circular relating to the offering of up to 354'038 registered common shares with a par value of CHF 0.10 per share (the "**Offer Shares**") of mondobiotech holding AG, Stans, Switzerland (the "**Company**") described in the Offering Circular of the Company dated 1 April 2011 and has been prepared in accordance with the listing rules of the SIX Swiss Exchange.

This Supplement must be read in conjunction with the Offering Circular and the supplement dated 4 April 2011 ("**Supplement No. 1**"). Capitalised terms used and not defined in this Supplement have the meanings given to them in the Offering Circular. Prospective investors should read both this Supplement and the entire Offering Circular as amended by Supplement No. 1 and, in particular, for a discussion of certain risks that should be considered in connection with the Company and an investment in the Offer Shares, see "4 Risk Factors" in the Offering Circular.

This Supplement does not constitute: (i) an offer to sell, or a solicitation of an offer to buy any securities other than the Offer Shares, or (ii) an offer to sell, or the solicitation of an offer to buy, the Offer Shares by any person in any circumstances in which such offer or solicitation is unlawful. The restrictions that apply to the distribution of the Offering Circular also apply to the distribution of this Supplement. Potential investors with registered addresses or otherwise resident in territories subject to any offer or transfer restrictions are required by the Company to inform themselves about and observe any restrictions on the offer, sale or transfer of the Offer Shares and the distribution of this Supplement and the Offering Circular, and to refer to the section "1 Notice to Investors" and "17 Selling and Transfer Restrictions" of the Offering Circular for further information.

This Supplement together with the Offering Circular and Supplement No. 1 collectively constitute the final listing prospectus. Copies of this Supplement, the Offering Circular and any supplements (including Supplement No. 1) thereto, are available on the Company's website (www.mondobiotech.com) and free of charge at the offices of mondobiotech holding AG, Mürzgstrasse 18, CH - 6370 Stans, (tel.: +41 (0) 840 200 010, fax: +41 (0) 840 200 011, email: investor@mondobiotech.com).

Number of Offer Shares issued	In the Offering, the Company has received subscriptions for 165'042 Offer Shares.
Net Proceeds	The Company estimates that the net proceeds of the Offering will be approximately CHF 7.35 million, after deduction of expected expenses, fundraising commissions to third parties and Swiss Federal Issuance Stamp Tax (<i>Emissionsabgabe</i>) of 1%.
Capital Structure	<p>After completion of the Offering, the issued share capital of the Company will be CHF 689'175.80, divided into 52'901'560 Voting Right Shares and 1'601'602 Common Shares with a nominal value of CHF 0.01 and CHF 0.10 each, respectively, and the authorized share capital of the Company will be CHF 291'648.20. The newly issued Common Shares will constitute 0.30% of the voting rights in the Company, 2.39% of the issued share capital of the Company and 10.30% of the Common Shares.</p> <p>Immediately after the Offering, the Company will have issued and listed on the SIX Swiss Exchange 1'601'602 Common Shares equalling 2.94% of the then existing voting rights in the Company and 23.24% of the then issued share capital of the Company.</p>
Listing and first trading day of Offer Shares	15 April 2011
Delivery of Offer Shares	18 April 2011
Ticker Symbol (Common Shares)	RARE
Swiss Security Number (Valorenummer) / ISIN	Common Shares: 10191073 / CH0101910732 Voting Right Shares: 10019113 / CH0100191136